A New Horizon For Cancer Therapy

The Biokine Story

Biokine Therapeutics Ltd. (Biokine) is a clinical-stage biopharmaceutical company developing novel drugs to treat cancer. Biokine is devoted to identifying novel molecular and cellular mechanisms that regulate tumor development and metastasis. Founded in 2000 by Prof. Amnon Peled, a leading cancer and stem cell biologist at Hadassah University Hospital, Biokine has completed more than 14 years of R&D and clinical research. Using its knowhow and suite of unique approaches to target cancer, Biokine identified the high-affinity CXCR4 antagonist BKT140/BL8040 as a drug candidate to treat a variety of cancers. BKT140/BL8040 is currently in a Phase IIa clinical trial for the treatment of refractory and relapsed Acute Myeloid Leukemia (AML), as well as a Phase I clinical trial for the mobilization of stem cells.   Recently, Biokine discovered novel kinase inhibitors with the ability to eradicate tumor cells and block chemokine receptor signaling. Biokine intends to advance the development of these antagonists into Phase I clinical trials.

Our Mission

The mission of Biokine is devoted to identifying novel molecular and cellular mechanisms that regulate tumor development and metastasis and to develop novel therapeutics against these devastating diseases.

Why Cancer?

According to estimates from the International Agency for Research on Cancer (IARC), there were 12.7 million new cancer cases in 2008 worldwide,of which 5.6 million occurred in economically developed countries and 7.1 million in economically developing countries. The corresponding estimates for total cancer deaths in 2008 were 7.6 million (about 21,000 cancer deaths a day), 2.8 million in economically developed countries and 4.8 million in economically developing countries. By 2030, the global burden is expected to grow to 21.4 million new cancer cases and 13.2 million cancer deaths simply due to the growth and aging of the population, as well as reductions in childhood mortality and deaths from infectious diseases in developing countries.
In 2014, there will be an estimated 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in the US. Cancer remains the second most common cause of death in the US, accounting for nearly 1 of every 4 deaths.
Global Cancer Facts & Figures   www.cancer.org